Power Law company profile

Kymab

Biotech & Life Sciences · Babraham, United Kingdom · Founded 2010 Unicorn

Human monoclonal antibody discovery and development platform

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Revenue

$1–10M

Latest reported FY

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

7 investors on Kymab's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Wellcome Trust

Series B+ 6 investors entered at this stage

Malin Corporation

Bill & Melinda Gates Foundation

ORI Capital

Wellcome Trust Sanger Institute

Woodford Investment Management

Hepalink

Global footprint

Where Kymab has talent and traffic

Workforce by country

🇬🇧 United Kingdom · Babraham HQ

Book a demo for the full country breakdown

Web traffic by country

20 monthly visits
across markets

🇬🇧 United Kingdom3000%

Top 1 markets shown

Market sentiment

What the market is saying about Kymab

An AI-synthesized read of the highest-engagement posts about Kymab on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kymab on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles